TITLE 18. PROFESSIONAL AND OCCUPATIONAL LICENSING
REGISTRAR'S NOTICE: The
Board of Pharmacy is claiming an exemption from Article 2 of the Administrative
Process Act in accordance with § 2.2-4006 A 13 of the Code of Virginia,
which exempts amendments to regulations of the board to schedule a substance
pursuant to subsection E of § 54.1-3443 of the Code of Virginia. The board
will receive, consider, and respond to petitions by any interested person at
any time with respect to reconsideration or revision.
Title of Regulation: 18VAC110-20. Regulations
Governing the Practice of Pharmacy (amending 18VAC110-20-323).
Statutory Authority: §§ 54.1-2400 and 54.1-3443 of the
Code of Virginia.
Effective Date: February 6, 2019.
Agency Contact: Caroline Juran, RPh, Executive Director,
Board of Pharmacy, 9960 Mayland Drive, Suite 300, Richmond, VA 23233-1463,
telephone (804) 367-4456, FAX (804) 527-4472, or email
caroline.juran@dhp.virginia.gov.
Summary:
The amendment adds one compound into Schedule V of the Drug
Control Act pursuant to § 54.1-3443 E of the Code of Virginia to mirror a
federal action, which does the same, and after the expiration of 30 days from
publication in the Federal Register of the final federal rule.
18VAC110-20-323. Scheduling for conformity with federal law or
rule.
Pursuant to subsection E of § 54.1-3443 of the Code of
Virginia and in order to conform the Drug Control Act to recent scheduling
changes enacted in federal law or rule, the board:
1. Adds MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine)
to Schedule I;
2. Adds Dronabinol ((-)-delta-9-trans tetrahydrocannabinol) in
an oral solution in a drug product approved for marketing by the U.S. Food and
Drug Administration to Schedule II; and
3. Deletes naldemedine from Schedule II; and
4. Adds a drug product in finished dosage formulation that
has been approved by the U.S. Food and Drug Administration that contains
cannabidiol
(2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol)
derived from cannabis and no more than 0.1% (w/w) residual
tetrahydrocannabinols to Schedule V.
VA.R. Doc. No. R19-5748; Filed December 12, 2018, 12:01 p.m.